keyword
MENU ▼
Read by QxMD icon Read
search

paclitaxel cancer

keyword
https://www.readbyqxmd.com/read/29653223/acid-sensitive-hybrid-polymeric-micelles-containing-a-reversibly-activatable-cell-penetrating-peptide-for-tumor-specific-cytoplasm-targeting
#1
Baoqiang Tang, Jennica L Zaro, Yan Shen, Qian Chen, Yinglan Yu, Pingping Sun, Yanqi Wang, Wei-Chiang Shen, Jiasheng Tu, Chunmeng Sun
Cell-penetrating peptides (CPPs) have become a novel drug delivery system due to their distinct advantages, including high cell transmembrane potency and ability to carry cargo molecules inside cells. However, owing to their cationic charge and non-specificity characteristics, the clinical application of CPPs is limited. In the current study, we engineered a reversibly activatable cell-penetrating peptide (RACPP), containing oligoarginine fused to a pH-sensitive masking sequence via a polyglycine linker ((HE)10 G5 R6 or HE-CPP) with ultra-pH-sensitivity...
April 10, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29651946/neoadjuvant-therapy-is-essential-for-resectable-pancreatic-cancer
#2
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Shuo Li, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
BACKGROUND: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. METHODS: In this review, we examined available data on neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials...
April 12, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29651809/development-of-chemotherapy-and-significance-of-conversion-surgery-after-chemotherapy-in-unresectable-pancreatic-cancer
#3
REVIEW
Junji Furuse, Junji Shibahara, Masanori Sugiyama
While surgery currently remains the only potentially curative treatment available for pancreatic cancer, only 20% to 30% of patients have resectable disease at diagnosis. Recently, with the introduction of intensive chemotherapy regimens such as oxaliplatin, irinotecan, fluorouracil plus leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel, for the treatment of unresectable pancreatic cancer, the antitumor activity and overall survival in patients with pancreatic cancer have dramatically improved. These advances in intensive chemotherapy have led to the possibility of conversion of unresectable disease to resectable disease, and it has been reported that more than 20% of pancreatic cancer patients with unresectable locally advanced disease at diagnosis undergo successful conversion surgery after FOLFIRINOX therapy...
April 12, 2018: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/29650939/-a-case-of-successful-treatment-with-gemcitabine-plus-nab-paclitaxel-therapy-for-nonresected-pancreatic-body-cancer-stage-ivb
#4
Jun Kaneko, Ayako Kamiya, Kenta Kobayashi, Yasushi Takatsuno, Ito Kondoh, Kentaro Maejima, Jun Isogai, Kumi Hasegawa, Takeshi Endo, Shizuaki Maejima
A 61-year-old woman was introduced for consultation with a chief complaint of frequent vomiting. CT revealed a pancreatic body cancer approximately 40mm in size; an invading stenosis from the horizontal part of the duodenum to the jejunum, superior mesenteric artery, and portal vein, splenic vein obstruction, lymphadenopathy, and some ascitic fluid. We diagnosed a passage disorder due to the invasive stenosis from the horizontal part of the duodenum of the pancreatic body cancer to the jejunum, and subsequently performed a duodenum and jejunum bypass operation...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650845/-a-case-report-of-sox-treatment-for-primary-duodenal-carcinoma-with-liver-metastasis
#5
Yuki Yokota, Hirotsugu Nagase, Kozo Noguchi, Atsushi Hamabe, Masashi Hirota, Kazuteru Oshima, Tsukasa Tanida, Yoshito Tomimaru, Tomono Kawase, Shunji Morita, Hiroshi Imamura, Takashi Iwazawa, Kenzo Akagi, Keizo Dono
We report a case of effective S-1 plus oxaliplatin (SOX) treatment for duodenal cancer with liver metastases. The patient was a 70-year-old female diagnosed with duodenal carcinoma that was unresectable because of liver metastasis(cT4N1M1, cStage IV in UICC 7th). She received SOX treatment(100mg/m / 2 of oxaliplatin on day 1 combined with 40 mg/day of S-1 twice daily on days 1-14, was repeated every 3 weeks). After 4 courses, a partial response was confirmed by computed tomography and no severe adverse events were observed...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650840/-a-case-of-effective-palliative-care-with-cart-for-refractory-ascites-associated-with-cancerous-peritonitis-of-gastric-cancer
#6
Junji Kawada, Masaya Nishino, Tomoki Hata, Takayuki Ogino, Hiromitsu Hoshino, Miho Okano, Kenichi Nagai, Yongkook Kim, Masaki Okuyama, Toshimasa Tsujinaka
Refractory ascites associated with cancerous peritonitis causes abdominal tension and reduced oral intake. Frequent ascites drainage can cause rapid worsening ofa patient's general condition. Cell-free and concentrated ascites reinfusion therapy (CART)for refractory ascites was first covered in 1981, and the general conditions ofpatients and their symptoms could be improved after undergoing CART. Herein, we report a case of effective palliative care with CART for refractory ascites associated with cancerous peritonitis...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650273/dose-dense-weekly-chemotherapy-in-advanced-ovarian-cancer-an-updated-meta-analysis-of-randomized-controlled-trials
#7
REVIEW
C Marchetti, F De Felice, A Di Pinto, O D'Oria, N Aleksa, A Musella, I Palaia, L Muzii, V Tombolini, P Benedetti Panici
OBJECTIVE: The use of dose-dense weekly chemotherapy in the management of advanced ovarian cancer (OC) remains controversial. The aim of this meta-analysis was to evaluate the efficacy of dose-dense regimen to improve clinical outcomes in OC patients with the inclusion of new trials. METHODS: For this updated meta-analysis, PubMed Medline and Scopus databases and meeting proceedings were searched for eligible studies with the limitation of randomized controlled trials, comparing dose-dense chemotherapy versus standard treatment...
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29650042/dental-pulp-stem-cells-used-to-deliver-the-anticancer-drug-paclitaxel
#8
Hamideh Salehi, Siham Al-Arag, Elodie Middendorp, Csilla Gergely, Frederic Cuisinier, Valerie Orti
BACKGROUND: Understanding stem cell behavior as a delivery tool in cancer therapy is essential for evaluating their future clinical potential. Previous in-vivo studies proved the use of mesenchymal stem cells (MSCs) for local delivery of the commonest anticancer drug, paclitaxel (PTX). Dental pulp is a relatively abundant noninvasive source of MSCs. We assess dental pulp stem cells (DPSCs), for the first time, as anticancer drug carriers. Confocal Raman microscopy is a unique tool to trace drug and cell viability without labeling...
April 12, 2018: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29649747/polymeric-micelles-theranostic-co-delivery-system-for-poorly-water-soluble-drugs-and-contrast-agents
#9
Jaydev R Upponi, Kaushal Jerajani, Dattatri K Nagesha, Praveen Kulkarni, Srinivas Sridhar, Craig Ferris, Vladimir P Torchilin
Interest in theranostic agents has continued to grow because of their promise for simultaneous cancer detection and therapy. A platform-based nanosized combination agent suitable for the enhanced diagnosis and treatment of cancer was prepared using polymeric polyethylene glycol-phosphatidylethanolamine-based micelles loaded with both, poorly soluble chemotherapeutic agent paclitaxel and hydrophobic superparamagnetic iron oxide nanoparticles (SPION), a Magnetic Resonance Imaging contrast agent. The co-loaded paclitaxel and SPION did not affect each other's functional properties in vitro...
March 31, 2018: Biomaterials
https://www.readbyqxmd.com/read/29649145/combined-effect-of-anticancer-agents-and-cytochrome-c-decorated-hybrid-nanoparticles-for-liver-cancer-therapy
#10
Wejdan Al-Shakarchi, Ali Alsuraifi, Mohammed Abed, Marwan Abdullah, Alan Richardson, Anthony Curtis, Clare Hoskins
Hepatocellular carcinoma is an aggressive form of liver cancer that displays minimal symptoms until its late stages. Unfortunately, patient prognosis still remains poor with only 10% of patients surviving more than five years after diagnosis. Current chemotherapies alone are not offering efficient treatment, hence alternative therapeutic approaches are urgently required. In this work, we highlight the potential of combination of treatment of hepatocellular carcinoma with existing chemotherapies in combination with pro-apoptotic factor cytochrome C...
April 12, 2018: Pharmaceutics
https://www.readbyqxmd.com/read/29649113/new-and-old-genes-associated-with-primary-and-established-responses-to-paclitaxel-treatment-in-ovarian-cancer-cell-lines
#11
Monika Świerczewska, Andrzej Klejewski, Maciej Brązert, Dominika Kaźmierczak, Dariusz Iżycki, Michał Nowicki, Maciej Zabel, Radosław Januchowski
Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ovarian cancer. Paclitaxel (PAC) is a chemotherapeutic drug used in the treatment of this cancer. We analysed the development of PAC resistance in two ovarian cancer cell lines. Exposure of drug-sensitive cell lines (A2780 and W1) to PAC was used to determine the primary response. An established response was determined in PAC-resistant sublines of the A2780 and W1 cell lines. qRT-PCR was performed to measure the expression levels of specific genes...
April 12, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29644009/pomalidomide-enhanced-gemcitabine-and-nab-paclitaxel-on-pancreatic-cancer-both-in-vitro-and-in-vivo
#12
Nobuhiro Saito, Yoshihiro Shirai, Tadashi Uwagawa, Takashi Horiuchi, Hiroshi Sugano, Koichiro Haruki, Hiroaki Shiba, Toya Ohashi, Katsuhiko Yanaga
Background: Chemotherapy with gemcitabine and nab-paclitaxel (gemcitabine/nab-paclitaxel) is recommended for unresectable pancreatic cancer. However, the therapeutic efficacy is attenuated by the antitumor agent-induced activation of nuclear factor-κB (NF-κB). Thalidomide inhibits NF-κB activation, therefore, we hypothesized that pomalidomide, a third-generation IMiD, would also inhibit NF-κB activation and enhance the antitumor effects of gemcitabine/nab-paclitaxel. Methods: In vitro , we assessed NF-κB activity and apoptosis in response to pomalidomide alone, gemcitabine/nab-paclitaxel, or combination of pomalidomide and gemcitabine/nab-paclitaxel in human pancreatic cancer cell lines (PANC-1 and MIA PaCa-2)...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29643995/treatment-of-oral-cancer-using-magnetized-paclitaxel
#13
Rina Nakakaji, Masanari Umemura, Kenji Mitsudo, Jeong-Hwan Kim, Yujiro Hoshino, Itaru Sato, Takatsugu Masuda, Masahiro Yamamoto, Mitomu Kioi, Toshiyuki Koizumi, Takayuki Fujita, Utako Yokoyama, Masaki Iida, Motohiko Sato, Hiroshi Sato, Shoko Murofushi, Sayaka Shibata, Ichio Aoki, Haruki Eguchi, Iwai Tohnai, Yoshihiro Ishikawa
N,N'-Bis(salicylidene)ethylenediamine iron (Fe(Salen)) is an anti-cancer agent with intrinsic magnetic property. Here, we covalently linked Fe(Salen) to paclitaxel (PTX), a widely used anti-cancer drug, to obtain a magnetized paclitaxel conjugate (M-PTX), which exhibited magnetic characteristics for magnet-guided drug delivery and MRI visualization. M-PTX increased apoptosis and G2/M arrest of cultured human oral cancer cell lines in the same manner as PTX. Furthermore, marked contrast intensity was obtained in magnetic resonance imaging (MRI) of M-PTX...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29628974/the-effect-of-near-infrared-fluorescence-conjugation-on-the-anti-cancer-potential-of-cetuximab
#14
Ji Young Yun, Byung-Hwa Hyun, Sang Yoon Nam, Young Won Yun, Hu-Jang Lee, Beom-Jun Lee
This study investigated the anti-cancer potential of a near-infrared fluorescence (NIRF) molecule conjugated with Cetuximab (Cetuximab-NIRF) in six-week-old female BALB/c athymic (nu+/nu+) nude mice. A431 cells were cultured and injected into the animals to induce solid tumors. Paclitaxel (30 mg/kg body weight (BW)), Cetuximab (1 mg/kg BW), and Cetuximab-NIRF (0.25, 0.5 and 1.0 mg/kg BW) were intraperitoneally injected twice a week into the A431 cell xenografts of the nude mice. Changes in BW, tumor volume and weight, fat and lean mass, and diameter of the peri-tumoral blood vessel were determined after two weeks...
March 2018: Laboratory Animal Research
https://www.readbyqxmd.com/read/29627688/chemosensitizing-effects-of-metformin-on-cisplatin-and-paclitaxel-resistant-ovarian-cancer-cell-lines
#15
Isabella Dos Santos Guimarães, Taciane Ladislau-Magescky, Nayara Gusmão Tessarollo, Diandra Zipinotti Dos Santos, Etel Rodrigues Pereira Gimba, Cinthya Sternberg, Ian Victor Silva, Leticia Batista Azevedo Rangel
BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. Primary cytoreductive surgery with adjuvant taxane-platinum chemotherapy is the standard treatment to fight ovarian cancer, however, their side effects are severe, and chemoresistance emerges at high rates. Therefore, EOC clinic urges for novel treatment strategies to reverse chemoresistance and to improve the survival rates. Metformin has been shown to act in synergy with certain anti-cancer agents, overcoming chemoresistance in various types of tumors...
November 21, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29625422/paclitaxel-and-di-fluorinated-curcumin-loaded-in-albumin-nanoparticles-for-targeted-synergistic-combination-therapy-of-ovarian-and-cervical-cancers
#16
Kaustubh A Gawde, Samaresh Sau, Katyayani Tatiparti, Sushil K Kashaw, Mohammad Mehrmohammadi, Asfar S Azmi, Arun K Iyer
Paclitaxel (PTX) encapsulated in albumin (Abraxane® ) is an FDA approved frontline nano-formulation for treating advance metastatic pancreatic, lung and breast cancers. Currently in clinic, Abraxane® is being used as a one of the components of combination therapy regimens. On the other hand, difluorinated curcumin (CDF) is a novel and potent synthetic curcumin analogue that is being evaluated for several malignancies including pancreatic, liver, ovarian and breast cancers. To improve the bioavailability and targeting ability of hydrophobic PTX and CDF, we have encapsulated them in folic acid decorated bovine serum albumin nanoparticles, namely FA-BSA-PTX and FA-BSA-CDF, respectively...
March 28, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29625142/substituents-at-the-c3-and-c3-n-positions-are-critical-for-taxanes-to-overcome-acquired-resistance-of-cancer-cells-to-paclitaxel
#17
Michael Jelínek, Kamila Balušíková, Petr Daniel, Vlasta Němcová-Fürstová, Palani Kirubakaran, Martin Jaček, Longfei Wei, Xin Wang, Jiří Vondrášek, Iwao Ojima, Jan Kovář
We tested the role of substituents at the C3' and C3'N positions of the taxane molecule to identify taxane derivatives capable of overcoming acquired resistance to paclitaxel. Paclitaxel-resistant sublines SK-BR-3/PacR and MCF-7/PacR as well as the original paclitaxel-sensitive breast cancer cell lines SK-BR-3 and MCF-7 were used for testing. Increased expression of the ABCB1 transporter was found to be involved in the acquired resistance. We tested three groups of taxane derivatives: (1) phenyl group at both C3' and C3'N positions, (2) one phenyl at one of the C3' and C3'N positions and a non-aromatic group at the second position, (3) a non-aromatic group at both C3' and C3'N positions...
April 3, 2018: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/29623757/icariin-a-flavonoid-with-anti-cancer-effects-alleviated-paclitaxel-induced-neuropathic-pain-in-a-sirt1-dependent-manner
#18
Yulong Gui, Jie Zhang, Liang Chen, Shunyuan Duan, Jing Tang, Wei Xu, Aiyuan Li
Background One of the most common side effects of paclitaxel was dosage-dependently painful neuropathy. Various reports indicated that spinal neuroinflammation was involved in paclitaxel-induced neuropathic pain. This study investigated the effect of icariin on paclitaxel-induced neuroinflammation and peripheral neuropathy in rats. Methods Two parts were included in this study. In part one, the effect of icariin on paclitaxel-induced neuropathic pain was investigated. Mechanical thresholds were measured as primary outcomes...
January 2018: Molecular Pain
https://www.readbyqxmd.com/read/29621664/chemotherapy-and-radiofrequency-induced-mild-hyperthermia-combined-treatment-of-orthotopic-pancreatic-ductal-adenocarcinoma-xenografts
#19
Martyna Krzykawska-Serda, Mahdi S Agha, Jason Chak-Shing Ho, Matthew J Ware, Justin J Law, Jared M Newton, Lam Nguyen, Steven A Curley, Stuart J Corr
Patients with pancreatic ductal adenocarcinomas (PDAC) have one of the poorest survival rates of all cancers. The main reason for this is related to the unique tumor stroma and poor vascularization of PDAC. As a consequence, chemotherapeutic drugs, such as nab-paclitaxel and gemcitabine, cannot efficiently penetrate into the tumor tissue. Non-invasive radiofrequency (RF) mild hyperthermia treatment was proposed as a synergistic therapy to enhance drug uptake into the tumor by increasing tumor vascular inflow and perfusion, thus, increasing the effect of chemotherapy...
April 2, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29620264/pegylated-liposomal%C3%A2-paclitaxel-induces-ovarian-cancer-cell-apoptosis-via-tnf%C3%A2-induced-erk-akt-signaling-pathway
#20
Zhiying Qi, Lirong Yin, Yanying Xu, Fang Wang
Ovarian cancer is one of the most common gynecological types of cancer and is characterized by a relatively high incidence and high mortality rate. Evidence has demonstrated that paclitaxel (PTX) is an effective therapeutic treatment for human ovarian cancer. In the present study, the inhibitory effects of pegylated liposomal (PL)‑PTX on the growth of ovarian cancer cells were investigated in vitro; a CAOV‑3‑bearing mouse model was established to investigate the in vivo effects of PL‑PTX on ovarian tumor growth...
March 28, 2018: Molecular Medicine Reports
keyword
keyword
68450
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"